PSCI

Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Partnership, NYSE, Wind, European, Corporation, GHG, Organization, Ozone, Urban Saints, PSCI, Renewable resource, Heat, Carbon, Electricity, RTC, Acid rain, Carbon accounting, CRL, VPPA, Green Power Partnership, Air pollution, Corporate social responsibility, Schneider Electric, Renewable energy

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable electricity globally.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable electricity globally.
  • Utilizing renewable electricity is a key component of the Company’s efforts to reduce greenhouse gas (GHG) emissions from facilities (Scope 1 & 2 emissions).
  • Charles River is expecting to meet the goal for achieving 100 percent renewable electricity globally by 2025, five years earlier than originally projected.
  • Charles River recognizes that collaboration across industries can help accelerate progress toward sustainability goals.

Sai Life Sciences joins Science Based Targets initiative (SBTi), commits to fight climate change with Science

Retrieved on: 
Thursday, June 22, 2023
Nxt, Greenhouse, Science, Science Based Targets initiative, Sustainable Development Goals, SDG, PSCI, Hazardous waste, GHG, Organizational culture, Temperature, Targets, Development, World Environment Day, Sustainability, Climate change, Contract research organization, Investment, Publishing, Paris, ESG, EHS, Renewable energy

HYDERABAD, India, June 22, 2023 (GLOBE NEWSWIRE) -- To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science.

Key Points: 
  • HYDERABAD, India, June 22, 2023 (GLOBE NEWSWIRE) -- To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science.
  • Accordingly, it has committed to set near-term company-wide emission reductions in line with climate science with the SBTi.
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sai Life Sciences has joined the SBTi to address a collective imperative.
  • In recent years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda as part of its organizational transformation initiative, Sai Nxt.

Piramal Pharma unveils its Sustainability Report FY21-22, articulating its ESG journey to accelerate the pace of integrating sustainability practices

Retrieved on: 
Thursday, October 13, 2022
Well, Zero, Allergan, Water, CSR, Quality, Growth, Coal, Ophthalmology, The Carlyle Group, ICH, ESG, Piramal, Tree, Patient, Sustainability, Report, Comparison of file archivers, Piramal Group, Workforce, PPL, Partnership, Goal, PSCI, Company, PPS, CDMO, CEO, CHG, Workplace, United Kingdom, Climate change, Chairperson, PCC, EHS, Renewable energy, Fine chemical, Audit, Environment

To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22

Key Points: 
  • To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22
    Nandini Piramal, Executive Director of Piramal Enterprises and Chairperson of Piramal Pharma Limited, says, "Piramal has always prioritised sustainability practices at its core across all its operations.
  • Our second Sustainability Report is a manifestation of the progress of this journey and provides our stakeholders with a transparent view of our ESG performance.
  • This year, PPLundertook specific objective targets and timelines to achieve its ESG goals as the next steps in its ESG journey.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.

Piramal Pharma unveils its Sustainability Report FY21-22, articulating its ESG journey to accelerate the pace of integrating sustainability practices

Retrieved on: 
Thursday, October 13, 2022
Well, Zero, Allergan, Water, CSR, Quality, Growth, Coal, Ophthalmology, The Carlyle Group, ICH, ESG, Piramal, Tree, Patient, Sustainability, Report, Comparison of file archivers, Piramal Group, Workforce, PPL, Partnership, Goal, PSCI, Company, PPS, CDMO, CEO, CHG, Workplace, United Kingdom, Climate change, Chairperson, PCC, EHS, Renewable energy, Fine chemical, Audit, Environment

To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22

Key Points: 
  • To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22
    Nandini Piramal, Executive Director of Piramal Enterprises and Chairperson of Piramal Pharma Limited, says, "Piramal has always prioritised sustainability practices at its core across all its operations.
  • Our second Sustainability Report is a manifestation of the progress of this journey and provides our stakeholders with a transparent view of our ESG performance.
  • This year, PPLundertook specific objective targets and timelines to achieve its ESG goals as the next steps in its ESG journey.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.

Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts

Retrieved on: 
Wednesday, September 28, 2022
Corporate social responsibility, Samsung Biologics, ESG, Ethics, PSCI, Recycling, Silver, Gold, Industry, RBA, CSR, Environment, CEO, Samsung, CDMO, Waste management, KRX, Fine chemical, Mobile phone

Achieving a score of 71/10014 points higher than its previous Silver rating in 2021Samsung Biologics is now among the top 5% of the more than 100,000 companies worldwide assessed by EcoVadis.

Key Points: 
  • Achieving a score of 71/10014 points higher than its previous Silver rating in 2021Samsung Biologics is now among the top 5% of the more than 100,000 companies worldwide assessed by EcoVadis.
  • "Achieving an EcoVadis Gold rating is further indication of Samsung Biologics' strengthened ESG focus and our commitment to working with our suppliers and industry partners to reduce our environmental impact, integrate sustainable management, and build a more transparent, responsible value chain," said John Rim, CEO and President of Samsung Biologics.
  • For more details and continuous updates on sustainability activities, please visit Samsung Biologics' Sustainability page .
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services.

SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative

Retrieved on: 
Thursday, February 24, 2022
ESG, Central nervous system, Sound, Health, Ethics, SK, Doctor of Philosophy, Central nervous system disease, Industry, Environment, Safety, Epilepsy, Multimedia, CEO, CNS, Fine chemical, Management, PSCI

PANGYO, GYEONGGI PROVINCE, South Korea, Feb. 24, 2022 /PRNewswire/ --SK Biopharmaceuticals, an innovative global pharmaceutical company, announced today that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member.

Key Points: 
  • PANGYO, GYEONGGI PROVINCE, South Korea, Feb. 24, 2022 /PRNewswire/ --SK Biopharmaceuticals, an innovative global pharmaceutical company, announced today that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member.
  • This marks the first time for a Korean company to be part of this industry group promoting sound and responsible supply chain management practices, human rights, and environmental sustainability around the world.
  • SK Biopharmaceuticals will ensure the principles are applied throughout its whole value chain, reaffirming its commitment to further enhancing its environmental, social and governance (ESG) management.
  • "We welcome SK Biopharmaceuticals as the first Korean company to join our group with a common vision to build sound global pharmaceutical supply chains," said Victoria Elizabeth Stone-Bjarup, Chair of the Pharmaceutical Supply Chain Initiative.

Sai Life Sciences Becomes First India-headquartered Company to Join Pharmaceutical Supply Chain Initiative (PSCI)

Retrieved on: 
Thursday, April 2, 2020
PSCI, Sai, Puttaparthi

HYDERABAD, India, April 2, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an 'Associate Member'.

Key Points: 
  • HYDERABAD, India, April 2, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an 'Associate Member'.
  • Welcoming Sai Life Sciences into its fold, a PSCI spokesperson said, "PSCI and its members are delighted to welcome Sai Life Sciences into membership, PSCI's first member with its main headquarters in India.
  • The PSCI is a non-profit business membership organization with a vision to establish and promote responsible practices that continuously improve pharmaceutical supply chains.
  • Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.

Sai Life Sciences Becomes First India-headquartered Company to Join Pharmaceutical Supply Chain Initiative (PSCI)

Retrieved on: 
Thursday, April 2, 2020
PSCI, TPG Capital, Sai, Puttaparthi, Industries

HYDERABAD, India, April 2, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an 'Associate Member'.

Key Points: 
  • HYDERABAD, India, April 2, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs) , today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an 'Associate Member'.
  • Welcoming Sai Life Sciences into its fold, a PSCI spokesperson said, "PSCI and its members are delighted to welcome Sai Life Sciences into membership, PSCI's first member with its main headquarters in India.
  • The PSCI is a non-profit business membership organization with a vision to establish and promote responsible practices that continuously improve pharmaceutical supply chains.
  • Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments.